皇冠体育app

皇冠体育app VMD hosted a very successful stakeholder open meeting which this year was combined with the Veterinary Products Committee (VPC) and the pharmaceutical industry information event. 皇冠体育app day brought together a wide range of stakeholders from the pharmaceutical Industry, VPC members, wholesalers, consultants, the charity sector and the media.

Over 70 people attended the event which was opened by Professor Pete Borriello (CEO) and Abi Seager (Director of Authorisations) to hear the latest information about:

• the work of the VPC from its chair - Malcolm Bennett
• the VMD鈥檚 international work
• antimicrobial resistance
• animal use in Quality Control testing of Immunological Veterinary Medicinal Products
• the VMD鈥檚 joint inspections with the Medicines and Healthcare products Regulatory Agency
• Brexit鈥檚 implications for the supply and regulation of veterinary medicines
• the relevance of European regulations

David Catlow 鈥� a VMD Non-Executive Director and Clinical Director of the Blue Cross - gave a keynote speech on 鈥極pportunity in a Changing Landscape鈥� highlighting the VMD鈥檚 excellent work to ensure continued effective medicines regulation after Brexit.

皇冠体育appre were two new elements to the event. Over lunch attendees enjoyed displays and demonstrations from the VMD teams on:

• VMD鈥檚 Digital Services
• Adverse Event reporting
• Brexit readiness
• Special Imports
• Enforcement
• Communications

皇冠体育appre was also a drop-in 鈥楢sk an Assessor鈥� area where scientific assessors were on hand to answer questions about any aspect of the safety, quality and efficacy assessment processes for marketing authorisations applications for veterinary medicines.

皇冠体育app VMD has already received very positive feedback on the event, in particular its innovative format and content.

皇冠体育app event is part of the VMD鈥檚 ongoing work to engage with its stakeholders on medicines regulation.

Copies of the PowerPoint Presentation slides from the event are available on request from [email protected]